Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PMP-300E (Smart Watch): Portable Monitoring Device Study (PMP-300E)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01364740
Recruitment Status : Completed
First Posted : June 2, 2011
Results First Posted : January 27, 2017
Last Update Posted : January 27, 2017
Information provided by (Responsible Party):
Clete A. Kushida, Stanford University

Brief Summary:
Validation of Portable Monitoring Device PMP-300E for Identification of Obstructive Sleep Apnea.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Device: PMP-300E Device: In-lab PSG Phase 3

Detailed Description:
The purpose of the study is to validate an Obstructive Sleep Apnea portable monitoring device, PMP-300E. Validating process compared data collected by PMP-300E with data collected from in-lab polysomnography.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: PMP-300E: Validation of Portable Monitoring Device PMP-300E for Identification of Obstructive Sleep Apnea.
Study Start Date : June 2008
Actual Primary Completion Date : May 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: PMP-300E, In-Lab PSG
PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
Device: PMP-300E
Data collected from Level 3 device
Other Names:
  • SmartWatch
  • Portable Monitoring Device
  • Sleep Apnea
  • Home Study
  • Sleep Diagnostic Device

Device: In-lab PSG
Data collected from Type I In-Lab Polysomnography
Other Name: Sleep Study

Primary Outcome Measures :
  1. AHI [ Time Frame: One night ]
    Apnea-Hypopnea Index (number of events/hour of sleep). Hypopneas scored without EEG arousals.

Secondary Outcome Measures :
  1. Apnea Index [ Time Frame: One night ]
    Number of events/hour of sleep

  2. Hypopnea Index [ Time Frame: One night ]
    Number of events/hour of sleep. Hypopneas scored without EEG arousals.

  3. Oxygen Saturation [ Time Frame: One night ]
    Mean oxygen saturation

Other Outcome Measures:
  1. Attitude Toward Device Use Questionnaire Scores [ Time Frame: one night ]
    Questionnaire consisting of multiple questions, scored as 1 = disagree completely to 5 = agree completely, revealed the following mean scores

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Inclusion Criteria:

  • Age 18 and over.
  • Require a sleep diagnostic study by physician's order.
  • Able and willing to provide written informed consent.
  • Able to speak and read English.

Exclusion Criteria:Exclusion Criteria:

  • Participation in another interventional research study within the last 30 days.
  • Unstable medical or psychiatric conditions that would interfere with the demands of the study or the ability to commit to follow-up assessment. Examples include unstable congestive heart failure, neuromuscular disease, cancer, and renal failure.
  • Chronic respiratory failure or insufficiency with suspected or known neuromuscular disease, moderate or severe COPD or other pulmonary disorders, or any condition with an elevation of arterial carbon dioxide levels (> 45 mmHg) while awake or participants qualifying for oxygen therapy (arterial saturation 88% for more than five minutes).
  • Consumption of ethanol more than 4 nights per week. (CAGE criteria)
  • Use of recreational drug within the past 12 months.
  • Women who are pregnant or currently lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01364740

Layout table for location information
United States, California
Center for Human Sleep Research
Redwood City, California, United States, 94063
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Layout table for investigator information
Principal Investigator: Clete A. Kushida M.D., Ph.D. Stanford University
Layout table for additonal information
Responsible Party: Clete A. Kushida, Principle Investigator, Stanford University Identifier: NCT01364740    
Other Study ID Numbers: SU-04212009-2358
K073327 ( Registry Identifier: )
SPO 42154 ( Other Identifier: Stanford University, OSR )
eProtocol 13181 ( Other Identifier: Stanford University, IRB )
First Posted: June 2, 2011    Key Record Dates
Results First Posted: January 27, 2017
Last Update Posted: January 27, 2017
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases